Lacouture, Mario
Sibaud, Vincent
Article History
First Online: 30 October 2018
Compliance with Ethical Standards
:
: Medical writing assistance was funded by Laboratoires dermatologiques Avène. Mario Lacouture and Vincent Sibaud received funds from Laboratoires dermatologiques Avène for traveling to and presenting at the Entretiens d'Avène Americas conference. MEL is funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.
: Vincent Sibaud declares he received fees from Laboratoires dermatologiques Avène, Roche, Novartis, Bayer, Pierre Fabre and BMS. Mario Lacouture declares he has received consulting/advisory fees from Merck Sharp & Dohme Corporation, Galderma, Janssen Research & Development, LLC, Abbvie, Inc., Helsinn Healthcare SA, Novocure Inc., Boehringer Ingelheim Pharma GMBH & Co.KG, F. Hoffmann-La Roche AG, Allergan Inc., Amgen Inc., E.R. Squibb & Sons, L.L.C., Novartis Pharmaceuticals Corporation, EMD Serono, Inc., Astrazeneca Pharmaceuticals LP, Genentech, Inc, Leo Pharma Inc, Seattle Genetics, Debiopharm, Lindi, Bayer, Manner SAS, Menlo Ther, Celldex, Lutris, Pierre Fabre, Legacy Healthcare, Roche, Amryt Pharma, Johnson & Johnson, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Parexel, Adgero, Veloce, Berg, US Biotest and research funding from Veloce, Berg, US Biotest, BMS.
: This article is published as part of a journal supplement wholly funded by Laboratoires dermatologiques Avène.